A drug approved to treat breast cancer patients with mutations in the BRCA1 or BRCA2 genes may also benefit people who have other genetic mutations.
Researchers at UT Southwestern reported in the journal Nature Cancer that talazoparib successfully shrank the tumors of breast cancer patients with mutations in the PALB2 gene. Patients with this mutation would not have previously qualified for treatment with talazoparib, a type of cancer drug known as a PARP inhibitor.
“These patients would otherwise have very limited treatment options,” said Joshua Gruber, M.D., Ph.D., Assistant Professor of Internal Medicine at UT Southwestern and a member of the Harold C. Simmons Comprehensive Cancer Center. “This study expands the patient population that can benefit from PARP inhibitors.”
Like other PARP inhibitors, talazoparib works by blocking a protein that usually helps cells repair damaged DNA. Without the ability to repair their DNA, cancer cells accumulate damage and eventually die. In cancers that have other defects in this process – including those with BRCA1/2 mutations – the drug is particularly effective, dealing a fatal second blow to the DNA repair machinery.
In a landmark 2018 study, researchers focused on advanced breast cancer patients with BRCA mutations – which account for 5% to 10% of all breast cancer cases – and found that talazoparib increased their survival time. The Food and Drug Administration approved the drug for that group, and follow-up studies have found that talazoparib also works for prostate and pancreatic cancer patients with BRCA mutations.
In the new phase 2 trial, Dr. Gruber and colleagues tested the effectiveness of talazoparib in advanced cancer patients with less common gene mutations associated with DNA repair. Previous data has suggested that more than 17% of all cancers have such mutations.
Twenty patients were enrolled in the trial at Stanford University, where Dr. Gruber previously served. Thirteen had breast cancer, three had pancreatic cancer, and four had other tumor types. The patients had mutations in eight DNA repair genes. On average, they took a daily talazoparib pill for 23.8 weeks.
Among all patients, the average survival time was 5.6 months, and 20% had at least partial shrinkage of tumors. Because this was a phase 2 trial, there was not a control group to compare these data to, but the results were especially striking for patients with the PALB2 mutations: They survived 6.9 months on average, and all six patients (five with breast cancer, one with pancreatic cancer) had tumor shrinkage.
The findings underscore the increasing importance of genetic testing to guide treatment for cancer patients, Dr. Gruber said. The team is planning a follow-up trial at UT Southwestern to further understand which patients gain the most benefit from talazoparib.
About UT Southwestern Medical Center
UT Southwestern, one of the nation’s premier academic medical centers, integrates pioneering biomedical research with exceptional clinical care and education. The institution’s faculty has received six Nobel Prizes, and includes 24 members of the National Academy of Sciences, 18 members of the National Academy of Medicine, and 14 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,900 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide care in more than 80 specialties to more than 100,000 hospitalized patients, more than 360,000 emergency room cases, and oversee nearly 4 million outpatient visits a year.
(LS/Newswise)
